Sun Pharma enters licensing agreement with CMS for arthritis drug Tildrakizumab

The initial tenure of the agreement between Sun Pharma and CMS shall be 15 years from the first commercial sale of Tildrakizumab in Greater China and may be extended for an additional 3 years' subject to certain conditions defined in the agreement.

New Delhi: Sun Pharmaceutical Industries Ltd. (Sun Pharma) recently announced that one of its wholly-owned subsidiaries has entered into a licensing agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for the development and commercialization of Tildrakizumab, an innovative biologic product, for psoriasis and psoriatic arthritis in Greater China (including Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan).

Under terms of the license agreement, CMS will pay Sun Pharma an initial upfront payment, regulatory and sales milestone payments, and royalties on net sales, the terms of which are confidential. CMS will be responsible for the development, regulatory filings and commercialization of the product in China.

The initial tenure of the agreement shall be 15 years from the first commercial sale of Tildrakizumab in Greater China and may be extended for an additional 3 years' subject to certain conditions defined in the agreement.

Commenting on the same, Dilip Shanghvi, Managing Director, Sun Pharma said, "This licensing agreement marks our entry into the Greater China market which is the second largest pharmaceutical market globally. Sun Pharma is committed to growing its dermatology franchise, with Tildrakizumab as its lead product."

"We continue to build our pipeline and capabilities in this important therapeutic area of significant unmet need. We are excited to be partnering with a leading pharmaceutical company like CMS to offer Tildrakizumab as an alternative treatment for psoriasis and psoriatic arthritis in Greater China, " he added.